May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Are Antibiotics Effective Against Fusarium and Aspergillus?
Author Affiliations & Notes
  • S. Day
    Ophthalmology, UCSF, San Francisco, California
  • L. Prajna
    Microbiology,
    Aravind Eye Hospital, Madurai, India
  • S. Haug
    Ophthalmology, UCSF, San Francisco, California
  • A. Fothergill
    Fungal Testing Laboratory, Department of Pathology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas
  • V. Cevallos
    Ophthalmology, UCSF, San Francisco, California
  • R. Vijayakumar
    Microbiology,
    Aravind Eye Hospital, Madurai, India
  • N. V. Prajna
    Ophthalmology,
    Aravind Eye Hospital, Madurai, India
  • N. R. Acharya
    Ophthalmology, UCSF, San Francisco, California
  • S. D. McLeod
    Ophthalmology, UCSF, San Francisco, California
  • T. M. Lietman
    Ophthalmology, UCSF, San Francisco, California
  • Footnotes
    Commercial Relationships  S. Day, None; L. Prajna, None; S. Haug, None; A. Fothergill, None; V. Cevallos, None; R. Vijayakumar, None; N.V. Prajna, None; N.R. Acharya, None; S.D. McLeod, None; T.M. Lietman, None.
  • Footnotes
    Support  That Man May See, NEI U10-EY015114 and K23EY017897, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2496. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Day, L. Prajna, S. Haug, A. Fothergill, V. Cevallos, R. Vijayakumar, N. V. Prajna, N. R. Acharya, S. D. McLeod, T. M. Lietman; Are Antibiotics Effective Against Fusarium and Aspergillus?. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2496.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Given published reports of fungal keratitis which improved with antibiotic treatment alone, we tested the susceptibility of Fusarium and Aspergillus isolated from keratitis to amoxicillin, cefazolin, chloramphenicol, moxifloxacin, tobramycin, and benzalkonium chloride (BAK).

Methods: : 10 isolates of Fusarium and 10 isolates of Aspergillus from cases of fungal keratitis at Aravind Eye Hospital in South India were tested using microbroth dilution for susceptibility to amoxicillin, cefazolin, chloramphenicol, moxifloxacin, tobramycin, and BAK. For each combination of agent and organism, the MIC50 and MIC90 were determined.

Results: : BAK had the lowest MIC for both Fusarium (MIC50 = 32 µg/ml, MIC90 = 64 µg/ml) and Aspergillus (MIC50 and MIC90 = 16 µg/ml). Chloramphenicol had activity against both Fusarium (MIC50 = 1000 µg/ml, MIC90 = 2000 µg/ml) and Aspergillus (MIC50 = 2000 µg/ml, MIC90 = 4000 µg/ml), while moxifloxacin and tobramycin had activity against Fusarium but not Aspergillus. For Fusarium, moxifloxacin had a MIC50 = 1000 µg/ml and MIC90 = 2000 µg/ml, while tobramycin had a MIC50 = 500 µg/ml and MIC90 = 700 µg/ml. For comparison, we found that amphotericin B had a MIC50 of 0.5 µg/ml for both Fusarium and Aspergillus.

Conclusions: : The susceptibility of Fusarium to tobramycin, moxifloxacin, chloramphenicol, and BAK and of Aspergillus to chloramphenicol and BAK may explain anecdotal reports of fungal ulcers which improved with antibiotic treatment alone. In some cases, the antibiotic MICs were lower than the typically prescribed concentrations, especially for tobramycin which can be given in a fortified concentration of 14,000 µg/ml. The low concentration of BAK found in some antibiotic eyedrops may also be beneficial. Regardless, the MICs of antibiotics are not in the range of antifungal agents such as natamycin, amphotericin B, or voriconazole. Antibiotics may, however, have some effect on Fusarium and Aspergillus when used as initial treatment prior to identification of the pathologic organism.

Keywords: antibiotics/antifungals/antiparasitics • fungal disease • keratitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×